Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.

Kwon JS, Kim YS, Cho HH, Kee HJ, Hong MH, Kang WS, Jeong HY, Jeong MH, Ahn Y.

Atherosclerosis. 2013 Jun;228(2):332-8. doi: 10.1016/j.atherosclerosis.2013.03.008. Epub 2013 Mar 20.

PMID:
23561646
2.

Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.

Sheehy A, Hsu S, Bouchard A, Lema P, Savard C, Guy LG, Tai J, Polyakov I.

Cardiovasc Diabetol. 2012 Jun 21;11:75. doi: 10.1186/1475-2840-11-75.

3.

Origin of restenosis after drug-eluting stent implantation in hyperglycemia is inflammatory cells and thrombus.

Kwon JS, Kim YS, Cho AS, Kim JS, Jeong SY, Hong MH, Jeong MH, Ahn Y.

J Atheroscler Thromb. 2011;18(7):604-15. Epub 2011 Jun 1.

4.

Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.

Lee KM, Lee HJ, Kim MK, Kim HS, Jung GS, Hur SH, Kim HT, Cho WH, Kim JG, Kim BW, Lim JO, Choi HS, Lee KU, Park KG, Lee IK.

Atherosclerosis. 2009 Dec;207(2):391-8. doi: 10.1016/j.atherosclerosis.2009.06.016. Epub 2009 Jun 18.

PMID:
19586629
5.
6.

Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells.

Takigawa T, Tsurushima H, Suzuki K, Tsuruta W, Nakamura K, Matsumura A.

J Vasc Surg. 2012 Feb;55(2):506-16. doi: 10.1016/j.jvs.2011.07.087.

7.

Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.

Hytönen J, Leppänen O, Braesen JH, Schunck WH, Mueller D, Jung F, Mrowietz C, Jastroch M, von Bergwelt-Baildon M, Kappert K, Heuser A, Drenckhahn JD, Pieske B, Thierfelder L, Ylä-Herttuala S, Blaschke F.

Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1534-48. doi: 10.1161/ATVBAHA.115.306962. Epub 2016 Jun 9.

8.

Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.

Wang F, Li M, Cheng L, Zhang T, Hu J, Cao M, Zhao J, Guo R, Gao L, Zhang X.

Life Sci. 2008 Dec 19;83(25-26):828-35. doi: 10.1016/j.lfs.2008.09.027. Epub 2008 Oct 21.

PMID:
18983856
9.

Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.

Silva GV, Fernandes MR, Madonna R, Clubb F, Oliveira E, Jimenez-Quevedo P, Branco R, Lopez J, Angeli FS, Sanz-Ruiz R, Vaughn WK, Zheng Y, Baimbridge F, Canales J, Cardoso CO, Assad JA, Falotico R, Perin EC.

Catheter Cardiovasc Interv. 2009 May 1;73(6):801-8. doi: 10.1002/ccd.21879.

PMID:
19309735
10.

Catechin averts experimental diabetes mellitus-induced vascular endothelial structural and functional abnormalities.

Bhardwaj P, Khanna D, Balakumar P.

Cardiovasc Toxicol. 2014 Mar;14(1):41-51. doi: 10.1007/s12012-013-9226-y.

PMID:
24048981
11.

Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression.

Gao L, Wang F, Wang B, Gong B, Zhang J, Zhang X, Zhao J.

J Pharmacol Exp Ther. 2006 Jul;318(1):53-8. Epub 2006 Apr 4.

12.

Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury.

von Heesen M, Müller S, Keppler U, Strowitzki MJ, Scheuer C, Schilling MK, Menger MD, Moussavian MR.

Ann Transplant. 2015 Mar 26;20:160-8. doi: 10.12659/AOT.893031.

13.

Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.

Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.

JACC Cardiovasc Interv. 2014 May;7(5):471-81. doi: 10.1016/j.jcin.2013.12.201.

14.

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).

Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ.

Am Heart J. 2010 Feb;159(2):284-291.e1. doi: 10.1016/j.ahj.2009.11.014.

PMID:
20152228
15.

Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.

Suzuki K, Uchida K, Nakanishi N, Hattori Y.

Am J Hypertens. 2008 Apr;21(4):451-7. doi: 10.1038/ajh.2008.6. Epub 2008 Feb 7.

PMID:
18369362
16.

Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.

Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.

Catheter Cardiovasc Interv. 2013 Apr;81(5):759-65. doi: 10.1002/ccd.24438. Epub 2012 Apr 23.

PMID:
22488756
17.

A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ.

JACC Cardiovasc Interv. 2011 Mar;4(3):310-6. doi: 10.1016/j.jcin.2010.12.006.

18.
19.

Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation.

Steigerwald K, Ballke S, Quee SC, Byrne RA, Vorpahl M, Vogeser M, Kolodgie F, Virmani R, Joner M.

EuroIntervention. 2012 Oct;8(6):752-9. doi: 10.4244/EIJV8I6A115.

20.

Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries.

Pendyala L, Yin X, Li J, Shinke T, Xu Y, Chen JP, King SB 3rd, Colley K, Goodchild T, Chronos N, Hou D.

EuroIntervention. 2010 May;6(1):126-33. doi: 10.4244/.

PMID:
20542808

Supplemental Content

Support Center